OncoMatch/Clinical Trials/NCT03647072
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
Is NCT03647072 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including CHOP and CHOP Plus Lanzoprazole for lymphoma.
Treatment: CHOP · CHOP Plus Lanzoprazole · CHOP Plus Famotidine — The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03647072 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages